Targeting Melanoma-Specific Tyrosinase: Cyclic Peptide Disrupts Actin Dynamics for Precision Apoptosis Induction

Publication date: Jul 08, 2025

Melanoma is an aggressive and highly metastatic cancer that exhibits stubborn resistance to conventional therapies, highlighting the need for novel treatments. Existing therapeutic strategies often suffer from systemic toxicity, poor efficacy and fast-gained drug resistance. In this study, we designed a cyclic peptide system (c-RGDKYQ) that takes the advantage of the overexpression of tyrosinase in melanoma cells to trigger enzyme-mediated oxidation and self-assembly. The assembled peptide nanostructures can selectively disrupt the actin cytoskeleton, impairing cancer cellular functions, e.g., motility, adhesion, and proliferation, ultimately leading to apoptosis. This approach does not rely on external drug payloads or complex delivery mechanisms. c-RGDKYQ exhibits high selectivity for melanoma cells, strongly suppressing tumor growth in a murine model with minimal systemic toxicity. Our findings illuminate that, through targeting tyrosinase, c-RGDKYQ may be an enzyme-responsive alternative to conventional treatments for melanoma.

PDF

Semantics

Download Document